With Interchangeability Nod, Viatris' Semglee Loses Its Identity
Executive Summary
Now approved as an interchangeable biosimilar, US labeling for Viatris’ insulin aspart mirrors that of Sanofi’s Lantus and has shed data from two studies in type 1 and 2 diabetics that showed noninferiority to Sanofi’s Lantus; Viatris appears in line for one year of exclusivity.
You may also be interested in...
Biosimilar Interchangeability Designation Would Be Nixed Under Biden Proposal
The proposal is not expected to cost or save the government money, but is expected to increase biosimilar uptake, according to budget documents.
Biosimilar Interchangeability Designation Would Be Nixed Under Biden Proposal
The proposal is not expected to cost or save the government money, but is expected to increase biosimilar uptake, according to budget documents.
Biosimilars: US FDA’s Updated Scientific Thinking Led To Interchangeability For Amgen's Wezlana
Pink Sheet’s Drug Review Profile explores Amgen’s Wezlana, an interchangeable biosimilar to Janssen’s Stelara. FDA determined late in the review that switching studies generally would not be needed for interchangeable ustekinumab products, prompting Amgen to seek the designation.